id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12862 R48540 |
Thomas (Valproate) (Controls exposed to Lamotrigine, sick), 2021 | Gastro-intestinal malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.15 [0.00;7.41] C excluded (control group) |
0/341 0/50 | 0 | 341 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12864 R48552 |
Thomas (Valproate) (Controls unexposed, sick), 2021 | Gastro-intestinal malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.33 [0.01;8.16] C | 0/341 1/340 | 1 | 341 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9333 R32561 |
Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 | Gastrointestinal tract defect | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.51 [0.55;4.17] C | 7/1,220 8/2,098 | 15 | 1,220 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9325 R32509 |
Veiby (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Digestive | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick | Adjustment: No | 1.88 [0.42;8.46] C | 3/333 4/833 | 7 | 333 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 1.46 [0.65;3.30] | 23 | 1,894 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Controls unexposed, sick; 2: Valproate) (Controls exposed to Lamotrigine, sick; 3: Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 12862